Ticker Details
Apellis Pharmaceuticals, Inc. Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
IPO Date:	November 9, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.18B
Activated in VL:	False

Average Daily Range
Avg Daily Range:	$0.98 | 2.78%
Avg Daily Range (30 D):	$0.35 | 1.73%
Avg Daily Range (90 D):	$0.49 | 2.19%

Institutional Daily Volume
Avg Daily Volume:	1.16M
Avg Daily Volume (30 D):	1.62M
Avg Daily Volume (90 D):	1.94M

Trade Size
Avg Trade Size (Sh.):	78
Avg Trade Size (Sh.) (30 D):	69
Avg Trade Size (Sh.) (90 D):	73

Institutional Trades
Total Institutional Trades:	8,038
Avg Institutional Trade:	$3.49M
Avg Institutional Trade (30 D):	$5.83M
Avg Institutional Trade (90 D):	$6M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	4

Market Closing Trades
Avg Closing Trade:	$7.62M
Avg Closing Trade (30 D):	$10.75M
Avg Closing Trade (90 D):	$12.35M
Avg Closing Volume:	210.84K

News

Apr 7, 2026 @ 12:54 PM Biogen Taps Alloy Platform To Push Antisense Drug ... Source: Vandana Singh

Apr 3, 2026 @ 2:35 PM Deal Dispatch: McCormick, Unilever Merge, Sysco Ac... Source: Caroline Ryan

Mar 31, 2026 @ 2:16 PM Biogen Lands Two Fast-Growing Drugs In Blockbuster... Source: Vandana Singh

Mar 21, 2026 @ 11:19 PM This New $193 Million Bet Targets a Biotech With $... Source: Jonathan Ponciano

Feb 23, 2026 @ 12:00 PM Apellis Pharmaceuticals to Present at the TD Cowen... Source: Na

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$.36	$1.71	$-.33
Diluted EPS	$.36	$1.67	$-.33
Revenue	$1.02B	$458.58M	$178.49M
Gross Profit
Net Income / Loss	$44.99M	$215.72M	$-42.15M
Operating Income / Loss	$80.41M	$223.18M	$-33.29M
Cost of Revenue
Net Cash Flow	$82.36M	$109.14M	$11.64M
PE Ratio	113.08